Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4977613 | 1.00 | SLC18A3 (0.36) | SLC18A3SIGMAR1FFAR1OPRL1MTNR1B | |
| Trifluoroacetic Acid SCHEMBL4977681 | 0.97 | FFAR1 (0.36) | SLC18A3SIGMAR1FFAR1OPRL1S1PR5 | |
| Trifluoroacetic Acid SCHEMBL4977685 | 0.97 | FFAR1 (0.36) | SLC18A3SIGMAR1FFAR1OPRL1S1PR5 | |
| SCHEMBL4981442 | 0.92 | FFAR1 (0.36) | SLC18A3SIGMAR1FFAR1OPRL1S1PR1 | |
| SCHEMBL4981448 | 0.92 | FFAR1 (0.36) | SLC18A3SIGMAR1FFAR1OPRL1S1PR1 | |
| SCHEMBL4977638 | 0.92 | SLC18A3 (0.35) | SLC18A3SIGMAR1FFAR1OPRL1MTNR1B | |
| SCHEMBL4977642 | 0.92 | SLC18A3 (0.35) | SLC18A3SIGMAR1FFAR1OPRL1MTNR1B | |
| SCHEMBL4977692 | 0.90 | SLC18A3 (0.34) | SLC18A3SIGMAR1FFAR1OPRL1 | |
| Trifluoroacetic Acid SCHEMBL4975890 | 0.90 | S1PR5 (0.36) | SLC18A3SIGMAR1FFAR1OPRL1S1PR5 | |
| Trifluoroacetic Acid SCHEMBL4975899 | 0.90 | S1PR5 (0.36) | SLC18A3SIGMAR1FFAR1OPRL1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7354925-B2 | Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as ORL1-receptor antagonists | PFIZER INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7279486-B2 | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists | PFIZER INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-20050277659-A1 | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists | PFIZER JAPAN INC. (JP) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277659-A1 | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists | OPRL1, OGFRL1, ORMDL3 | SLC18A3 3734/4885SIGMAR1 10/4885FFAR1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.